TBPH Stock Analysis: Buy, Sell, or Hold?
TBPH - Theravance Biopharma, Inc.
$16.34
-0.30 (-1.80%)
▼
5d:
+0.31%
30d:
-1.03%
90d:
+17.3%
BUY
HIGH Confidence
Analysis Updated: Jun 15, 2026 12:00 AM ET
Earnings: Aug 12, 2026
Get Alerted When TBPH Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: TBPH shows strong fundamentals and good volume confirmation. Solid entry point despite fair pricing.
✅ BUY SIGNAL: TBPH shows strong fundamentals and good volume confirmation. Solid entry point despite fair pricing.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$28.35
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$17.60
7.2% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 11.6x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: TBPH is currently trading at $16.34, which is considered fair relative to its 30-day fair value range of $16.07 to $16.66. From a valuation perspective, the stock is trading at a premium (Forward PE: 13.3) compared to its historical average (11.6). At these levels, the market is pricing in 4.5% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, TBPH is in a downtrend. The price is approaching resistance at $16.67. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: TBPH has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, TBPH is in a downtrend. The price is approaching resistance at $16.67. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: TBPH has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$16.07 -
$16.66
Company Quality Score
60/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
79.5%
All Signals
- NEUTRAL: Price in fair range
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- NEUTRAL: Near Wall St target ($17.40)
- NEUTRAL: Market pricing in 4.5% annual earnings growth - fairly valued
Trading Range Analysis
30-Day Trading Range
$16.07 -
$16.66
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$15.52
Resistance Level
$16.67
Current Trend
Downtrend
Technical data as of
Jun 15, 2026
Fundamental Context
Forward P/E (Next Year Est.)
13.26
Wall Street Target
$17.40
(+4.6%)
Revenue Growth (YoY)
15.0%
Profit Margin
104.3%
Valuation Premium vs History
+4.5% premium
PE vs Historical
13.3 vs 11.6
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+4.5%
(market-implied from PE analysis)
1-Year Target
$17.39
(+5%)
2-Year Target
$18.17
(+9%)
3-Year Target
$18.99
(+14%)
3-Yr Target (if PE normalizes)
(PE: 13→12)
PE COMPRESSION
$16.61
(0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 21.9, Growth: 497.6%)
$92.84
(+458%)
Base:
(SPY PE: 13.3, Growth: 497.6%)
$56.16
(+238%)
Bear:
(PE: 11.3, Growth: 497.6%)
$47.74
(+187%)
📈
Valuation based on Current Earnings
Trailing PE: 7.39 | Current EPS (TTM): $2.23
Bull Case
$10.21
(-39%)
Analyst growth -43.7%, PE expands to 8.1
Base Case
$9.28
(-44%)
Market implied -43.7%, PE stable at 7.4
Bear Case
$11.21
(-33%)
Severe decline -20.0%, PE contracts to 6.3
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: June 15, 2026 2:00 PM ET
Data refreshes hourly during market hours. Next update: 3:00 PM
Data refreshes hourly during market hours. Next update: 3:00 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is TBPH showing a specific setup today?
Insider Activity (6 Months)
0
Buys
1
Sells
Net
INSIDERS SELLING
Recent Transactions
Rhonda Farnum
SELL
31067 shares
2026-03-16
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
30 analysts |
$439 | 57 HOLD |
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$22 | 52 HOLD |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$34 | 67 BUY |
|
INSM
Insmed Inc |
STRONG BUY
21 analysts |
$198 | 56 HOLD |
|
RCKT
Rocket Pharmaceuticals I… |
STRONG BUY
18 analysts |
$9 | 50 HOLD |
